Tenderwize
Back to tender search

Open House Discount Contracts for Omalizumab

AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse·Eisenberg, Germany·Deadline Feb 28, 2027 · 145 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge zum Wirkstoff Omalizumab, ATC R03DX05

30/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

30 / 100

Complexity

20 / 100

Risk factors

No indication of expected sales volume or number of patients; the discount may not generate significant revenue.

The buyer may replace open house contracts with exclusive ones from a separate tender, automatically ending all open ho...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Tender facts

Contracting authority
AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse
Country
Germany
CPV
33600000 - Pharmaceutical products
Deadline
Feb 28, 2027

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Apr 2027
  • Conclusion of non-exclusive discount contracts (Rabattverträge) under German Social Code (§§ 130a Abs. 8/130c Abs. 1 SGB V) for Omalizumab.
  • Contracts are open to all pharmaceutical companies that supply authorized and marketable Omalizumab products in Germany.
Show full summary

Open house (non-exclusive) discount contracts for pharmaceutical products containing the active substance Omalizumab (ATC R03DX05), offered by AOK Rheinland-Pfalz/Saarland. The model allows any interested pharmaceutical company to enter into a standard agreement at any time during the 24-month period (May 2025 – April 2027). No competitive selection; all qualified applicants are accepted. The first contracts start 1 May 2025; initial application deadline is 31 March 2025. Later enrollments are possible monthly. The buyer may replace these non-exclusive contracts with exclusive ones during the term. The notice is published voluntarily for transparency; it is not a public procurement under EU directives.

Risks

No indication of expected sales volume or number of patients; the discount may not generate significant revenue.

The buyer may replace open house contracts with exclusive ones from a separate tender, automatically ending all open ho...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Provide authorized and marketable Omalizumab products in Germany (proof via Lauer-Taxe listing or AMIce database extracts).

Administrative

  • Submit signed contract documents and required annexes by applicable deadline.
  • No electronic submission; paper documents required (original by mail or courier).

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria defined; all eligible participants are accepted.

Buyer

Lots (1)

LOT-0001

Open House Discount Contracts for Omalizumab

Non-exclusive framework discount contracts for Omalizumab (ATC R03DX05). All pharmaceutical companies with authorized and marketable products in Germany can join. Standard terms, no negotiation. Max duration 24 months from earliest start (May 2025). Contracts end automatically if replaced by exclusive contracts from a separate tender.

SuppliesEU fundedElectronic submission

Location

Eisenberg, Germany

Duration

Apr 2025 - Apr 2027

Category

Pharmaceutical products

Award Criteria

No award criteria defined; all eligible participants are accepted.

Deadline

Deadline Feb 28, 2027

Procurement Details

Publication date
12 Mar 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
163311-2025

Documents (1)

Similar tenders